B · Normal
[Shanghai RAAS: Wholly-owned subsidiary received "Protein C" clinical trial approval notice] On November 16, Shanghai RAAS (002252.SZ) announced that the company's wholly-owned subsidiary Guangxi RAAS Biopharmaceutical Co., Ltd. received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration, agreeing to "Protein C" to conduct clinical trials for the treatment of patients with severe congenital protein C deficiency. This drug is the first domestic blood product for the treatment of rare diseases. Currently, no similar human protein C preparation has been approved for marketing in China. If it is successfully approved for marketing, the company's comprehensive utilization rate of plasma can be improved and its product layout can be optimized.
Comments